Novo Nordisk A/S
NVO
NYSE
12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Net Income | 3.17B | 3.28B | 2.84B | 2.85B | 1.87B |
Total Depreciation and Amortization | 94.56M | 368.75M | 318.08M | 247.68M | 141.62M |
Total Amortization of Deferred Charges | 30.75M | -- | -- | -- | 26.79M |
Total Other Non-Cash Items | -519.28M | 627.10M | 1.61B | 2.67B | -1.02B |
Change in Net Operating Assets | -1.40B | 1.70B | -586.64M | -1.47B | -42.31M |
Cash from Operations | 1.38B | 5.98B | 4.18B | 4.30B | 975.39M |
Capital Expenditure | -1.36B | -851.12M | -858.84M | -676.19M | -681.44M |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -971.82M |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -766.57M | -1.08B | -497.80M | -281.54M | -249.17M |
Cash from Investing | -2.12B | -1.93B | -1.36B | -957.73M | -1.90B |
Total Debt Issued | -- | -- | -- | -- | 95.00M |
Total Debt Repaid | -355.00M | -261.00M | -373.00M | -478.00M | -224.00M |
Issuance of Common Stock | -- | -- | -- | -- | -- |
Repurchase of Common Stock | -9.76B | -6.14B | -8.82B | -5.20B | -7.54B |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | 0.00 | -1.96B | 0.00 | -2.64B | 0.00 |
Other Financing Activities | -- | -- | -3.39B | 3.39B | -- |
Cash from Financing | -1.46B | -2.90B | -1.84B | -2.97B | -1.05B |
Foreign Exchange rate Adjustments | -30.17M | 61.04M | -9.50M | -37.89M | -115.93M |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -2.24B | 1.21B | 969.89M | 328.94M | -2.10B |